VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ISRGIntuitive Surgical, Inc.
$404.27$143.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksISRGCash Flow

Intuitive Surgical, Inc. (ISRG) Cash Flow Statement

27Y historyFree accessUpdated daily

Cash conversion remains robust with an OCF/NI ratio of 1.11, while capital expenditure intensity has moderated to 3.7% of revenue.

ISRG Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Cash from Operations3.36B3.03B2.42B1.81B1.49B2.09B1.48B1.6B1.17B1.14B1.04B771.9M665.1M880M814.2M677.6M528M385.06M278.24M205.69M99.84M70.79M30.32M-7.85M-14.15M-18.55M-12.8M-15.93M
Operating CF Margin %-30.11%28.91%25.46%23.96%36.59%34.07%35.69%31.41%36.56%38.56%32.37%31.2%38.85%37.37%38.56%37.37%36.6%31.8%34.23%26.79%31.14%21.84%-8.57%-19.64%-35.9%-48.09%-156.27%
Operating CF Growth %99.62%25.49%33.15%21.67%-28.65%40.72%-7.1%36.65%2.25%9.68%35.11%16.06%-24.42%8.08%20.16%28.33%37.12%38.39%35.27%106.01%41.05%133.5%485.98%44.49%23.74%-44.9%19.61%-
Net Income2.98B2.88B2.34B1.82B1.34B1.73B1.07B1.38B1.13B660M735.9M588.8M418.8M671M656.6M495.1M381.8M232.61M204.31M144.54M72.04M94.13M23.48M-9.62M-18.42M-16.7M-18.52M-18.41M
Depreciation & Amortization736.2M677.1M462M435.2M365.8M310.2M276.2M203M122.8M99.1M92.1M89.5M74.4M67.3M57.8M46.5M40.4M34.58M25.08M13.03M35.27M6.73M7.11M10.63M4.55M4.71M4.75M2.24M
Stock-Based Compensation812.5M788.2M676.8M598.2M513.2M449.2M395.4M335.8M261.2M209.1M177.6M167.9M168.9M168.9M153.3M136.4M117.6M96.98M036.29M25.26M4.75M0700K2.57M000
Deferred Taxes358.3M19.1M-135.3M-280.8M-185.3M-62.6M57.6M-8M31.9M62.9M18.7M4.6M-35M-38.5M-20.8M7.1M-21.5M-15.64M-20.5M3.91M9.08M-40.76M0-700K-2.57M000
Other Non-Cash Items-1.73B-58.2M-6.7M21.5M71.8M32.6M-38M7.1M12.4M21.2M21.6M13.6M23.8M33.3M32.8M12.4M-7.3M-1.5M79.27M5.95M-13.63M15.71M283K892K66K-87K0150K
Working Capital Changes190.9M-1.27B-919.3M-777.6M-619.1M-368.1M-273.2M-321.5M-383.7M91.6M-3M-92.5M14.2M-22M-65.5M-19.9M17M38.03M-9.94M1.97M-28.18M-9.78M-557K-9.75M-342K-6.48M967K95K
Change in Receivables-280.2M-301.7M-95.9M-186.3M-159.3M-142.3M5.7M38.8M-161.3M-81.7M-35.9M-79.2M-13.7M68.9M-68.9M-51.1M-41.5M-35.27M0-35.69M-41.85M-17.46M0-6.35M-4.4M000
Change in Inventory-1.12B-1.06B-830M-712.5M-546.6M-256M-170.1M-360.5M-279M-115.5M-46.7M-10.7M-26.8M-70M-7.1M-25.3M-29.2M5.86M-31.06M-8.21M-9.02M-9.21M2.82M4.62M-2.56M-106K-3.21M-1.6M
Change in Payables48.7M57.9M-400K41.7M21.3M36M-32.3M12.3M16.7M14M15.9M-11.3M17.7M-8.9M8.4M10.3M8.1M7.04M018.65M3.11M3.5M0-4.78M4.41M000
Cash from Investing-462.2M665.8M-3.27B-360.1M1.37B-2.46B-940.6M-1.15B-1.05B378.7M-1.28B-849.5M-153.9M259M-845.7M-479M-476.5M-292.38M-304.53M-236.4M-113.35M-103.31M-48.15M-71.18M18.17M5.61M-50.82M-10.31M
Capital Expenditures-526.5M-539.8M-1.11B-1.06B-532.4M-353.5M-341.5M-425.6M-187.4M-190.7M-53.9M-81M-105.6M-104.6M-141.8M-82.9M-96M-53.42M-105.97M-24.01M-18.05M-30.05M-22.44M-2.52M-5.79M-5.53M-3.56M-931K
CapEx % of Revenue4.98%5.36%13.3%14.94%8.56%6.19%7.84%9.5%5.03%6.09%1.99%3.4%4.95%4.62%6.51%4.72%6.79%5.08%12.11%4%4.84%13.22%16.17%2.75%8.04%10.7%13.35%9.13%
Acquisitions-12.7M-13.9M-1M-8.9M-12.8M-8.7M-37.7M-59.7M-87.9M190.7M53.9M81M-84.3M104.6M141.8M000304.53M19.93M18.05M10K0-8.46M-40K000
Investments----------------------------
Other Investing-483.4M0000000-774.3M-190.7M-53.9M-81M36M-104.6M-141.8M000-304.53M-19.93M-18.05M-1.17M306K275K62K36K-3M0
Cash from Financing-3.48B-2.36B150.9M-287.6M-2.57B43M-85.7M-168.4M126.3M-1.91B558.5M193.4M-692.4M-910.6M119.2M-12.4M7.7M-66.17M97.98M118.85M42.18M32.32M12.12M82.33M3M771K82.17M20.18M
Debt Issued (Net)000000000000000000000-608K-1.12M-1.62M947K-1.48M-259K822K
Equity Issued (Net)-2.08B-1.95B429.4M-416.3M-2.37B276.5M174.5M-269.5M236.6M-1.86B538.4M177.4M-716.4M-948.6M25M-71.2M-57.5M-91.31M44.68M55.98M19.14M32.92M13.23M83.96M2.06M2.25M82.43M19.36M
Dividends Paid0000000000000000000000000000
Share Repurchases-3.42B-2.3B0-416.3M-2.61B0-134.3M-269.5M0-2.27B-42.5M-183.7M-1B-1.11B-238.3M-331.8M-198.6M-150M000-72K0-6K-2K-65K-20K-43K
Other Financing-1.4B-419.1M-278.5M128.7M-198.7M-233.5M-260.2M101.1M-110.3M-54.6M20.1M16M24M38M94.2M58.8M65.2M25.14M53.3M62.87M23.04M0000000
Net Change in Cash-561.6M1.34B-707.7M1.17B294.7M-332.5M455.9M273.2M246.2M-388.4M322M114.3M-181.8M228.4M87.9M186M58.4M26.81M71.8M88.44M28.88M-263K-5.56M3.28M7.12M-12.17M18.55M-6.06M
Free Cash Flow2.83B2.49B1.3B749.6M958.4M1.74B1.14B1.17B982.2M953.2M989M690.9M559.5M775.4M672.4M594.7M432M331.64M172.26M181.68M81.79M40.73M7.88M-10.38M-19.94M-24.08M-16.36M-16.86M
FCF Margin %26.78%24.75%15.61%10.52%15.4%30.4%26.23%26.18%26.37%30.46%36.57%28.98%26.25%34.23%30.86%33.84%30.57%31.52%19.69%30.24%21.95%17.92%5.67%-11.32%-27.68%-46.6%-61.44%-165.4%
FCF Growth %62.4%91.03%73.93%-21.79%-44.79%51.83%-2.5%19.39%3.04%-3.62%43.15%23.49%-27.84%15.32%13.07%37.66%30.26%92.52%-5.18%122.13%100.8%417.18%175.88%47.94%17.21%-47.2%2.96%-
FCF per Share7.886.873.602.102.654.753.173.272.762.732.802.031.652.151.821.641.190.940.480.520.240.120.03-0.05-0.12-0.15-0.15-0.77
FCF Conversion (FCF/Net Income)0.95x1.06x1.04x1.01x1.13x1.23x1.40x1.16x1.04x1.73x1.42x1.31x1.59x1.31x1.24x1.37x1.38x1.66x1.36x1.42x1.39x0.75x1.29x0.82x0.77x1.11x0.69x0.86x
Interest Paid0000000000000000000000000000
Taxes Paid0537.9M466.5M447.8M444.2M000179.2M147.5M138.4M110.3M176.8M194.1M226.1M152M124.4M129.1M0000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Capital expenditure cycle volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality and Cash Conversion

As reported in recent financial statements, ISRG has demonstrated a significant improvement in cash conversion, with the OCF/NI ratio reaching 1.11 in 2026Q1, suggesting that the company is effectively translating its accounting profits into tangible cash inflows despite rising stock-based compensation expenses.

The consistent alignment between net income and operating cash flow indicates a high quality of earnings, largely devoid of aggressive accrual accounting. Investors should monitor whether this conversion efficiency persists as the company scales its newer platform iterations, which may carry different working capital requirements.

Free Cash Flow Margin Expansion

Based on the provided quarterly data, ISRG's free cash flow margin has recovered to 29.2% in 2026Q1, marking a substantial turnaround from the negative margins observed in 2023Q4 and reflecting the successful maturation of the company's recurring revenue model and disciplined cost management.

The trajectory of free cash flow suggests that the business is moving past the peak investment phase associated with recent product launches. This trend implies that the company is increasingly capable of self-funding its R&D initiatives while simultaneously generating excess liquidity for capital return programs.

Capital Intensity and Asset Replacement

According to historical filings, ISRG's capital expenditure as a percentage of revenue has moderated to 3.7% in 2026Q1, down from a peak of 22.6% in 2023Q4, indicating a transition toward a more efficient capital deployment phase following recent infrastructure and manufacturing capacity investments.

The reduction in capital intensity suggests that the company has largely completed the necessary heavy lifting for its current manufacturing footprint. This shift warrants further investigation into whether future capex will remain at these lower levels or if upcoming technological cycles will necessitate another period of elevated spending.

Disciplined Capital Allocation and Buybacks

As evidenced by recent cash flow statements, ISRG has utilized its robust cash generation to execute significant share repurchases, including $1.1 billion in 2026Q1, signaling management's confidence in the long-term value of the firm despite the absence of a formal dividend policy.

The aggressive use of cash for buybacks, rather than large-scale acquisitions, highlights a preference for returning capital to shareholders while maintaining a fortress balance sheet. This strategy appears to prioritize internal growth and share count reduction, which may support EPS growth in the absence of transformative M&A.

ISRG — Frequently Asked Questions

Quick answers to the most common questions about buying ISRG stock.

How much cash does Intuitive Surgical, Inc. (ISRG) generate from operations?

Intuitive Surgical, Inc. (ISRG) generated $3.03B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Intuitive Surgical, Inc.'s free cash flow?

Intuitive Surgical, Inc. (ISRG) generated $2.49B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Intuitive Surgical, Inc.'s capital expenditure (CapEx)?

Intuitive Surgical, Inc. (ISRG) spent $539.8M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Intuitive Surgical, Inc. distribute cash to shareholders?

In 2025, Intuitive Surgical, Inc. (ISRG) spent $2.30B on share repurchases. This shows the company's commitment to returning capital to its equity investors.